Can you provide a rough estimate for canakinumab's biosimilar launch?

What are the chances of canakinumab biosimilars entering the market?

Several biosimilar contenders are in various stages of development, as reported by the National Institute for Health and Care Excellence (NICE). [1] These companies aim to replicate the efficacy of canakinumab, a medication for treating certain inflammatory conditions such as systemic juvenile idiopathic arthritis and some inflammatory aspergillosis infections. However, regulatory hurdles and patent battles may limit the speed at which these biosimilars enter the market.

How does the patent situation affect the launch timeline?

According to DrugPatentWatch.com, Novartis' patent on canakinumab is set to expire in 2034 in the US [2]. However, generic manufacturers might face challenges from various patents filed by the original developer and subsequent patent filers, affecting the timing of generic entry into the market.

Which companies are in competition?

Novartis has licensed the US commercial rights for canakinumab to Amgen for the US market, which creates a competitive landscape for Amgen's biosimilar entry [3]. Nonetheless, there are still companies developing canakinumab biosimilars to enter other markets.

What does this mean for patients and the market?

The potential delay for launch means more time before new biosimilars enter the market, affecting competition. Competition between biosimilars can lower prices, provide more patient treatment options, and make healthcare more accessible. It is uncertain what exact timeline biosimilars will enter the market, however.

Sources:

[1] National Institute for Health and Care Excellence. (2022). Canakinumab.

[2] DrugPatentWatch.com. (2023). Canakinumab Patents.

[3] Reuters. (2021). Amgen gains US rights to Novartis' cancer drug canakinumab.